You are here:Home-Inhibitors & Agonists-Proteasome/Ubiquitin-p97/VCP

Request The Product List ofp97/VCP p97/VCP

Cat. No. Product Name CAS No. Information
PC-62542

MSC 1094308

2219320-08-6

MSC1094308 is a reversible, allosteric inhibitor of the type II AAA ATPase human ubiquitin-directed unfoldase (VCP)/p97 and the type I AAA ATPase VPS4B with IC50 of 7.2 and 0.71 uM, respectively; binds to drugable hotspot of p97, thereby inhibiting the D2 ATPase activity; is active in cells, and specifically inhibits p97 but not the proteasome.

PC-45718

ML-241

1346528-06-0

ML241 is a potent, selective and reversible AAA ATPase p97 inhibitor (IC50=100 nM); blocks degradation of p97-dependent proteasome substrate with an IC50 of 3.5 uM; induces caspases 3 and 7 and potently blocks proliferation in HCT15 and SW403 cells.

PC-45719

ML-241 hydrochloride

ML241 Hcl is a potent, selective and reversible AAA ATPase p97 inhibitor (IC50=100 nM); blocks degradation of p97-dependent proteasome substrate with an IC50 of 3.5 uM; induces caspases 3 and 7 and potently blocks proliferation in HCT15 and SW403 cells.

PC-45717

ML-240

1346527-98-7

ML240 is a potent, selective and reversible AAA ATPase p97 inhibitor (IC50=100 nM); blocks degradation of p97-dependent proteasome substrate with an IC50 of 0.9 uM; induces caspases 3 and 7 and potently blocked proliferation in HCT15 and SW403 cells.

PC-63243

UPCDC30245

1883351-01-6 UPCDC30245 is an allosteric inhibitor of AAA ATPase p97 with IC50 of 27 nM, binds at the junction between the D1 and D2 domains of p97.
PC-43263

CB-5083

1542705-92-9 CB-5083 is a potent, selective, orally bioavailable inhibitor of p97 AAA with IC50 of 11 nM, specifically targets D2 ATPase site of p97, shows 9.6, 128 and 158-fold less affinity for DNA-PK, mTOR and PIK3C3; causes accumulation of poly-ubiquitinated proteins, retention of ERAD substrates, and generation of irresolvable proteotoxic stress, leading to activation of the apoptotic arm of the unfolded protein response (UPR) in cancer cells; inhibits A549 cell viability with IC50 of 0.67 uM, induces the UPR and apoptosis in xenograft tumor models.

Blood Cancer

Phase 1 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com